Free shipping on all orders over $ 500

CR8

Cat. No. M7709

All AbMole products are for research use only, cannot be used for human consumption.

CR8 Structure
Size Price Availability Quantity
1mg USD 100  USD100 In stock
5mg USD 180  USD180 In stock
10mg USD 260  USD260 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

CR8 is a potent and selective inhibitor of cyclin dependent kinase (CDK1, 2, 5, 7, and 9). CR8 is a more potent pyridyl analogue of roscovitine (Cat. No. R7772). In comparison to roscovirtine, the compound gains in potency toward CK1, which is involved in amyloid-β formation. The R-CR8 enantiomer is slightly more potent than S. CR8 is around 30 times more potent at cellular assay then roscovitine.

Chemical Information
Molecular Weight 431.53
Formula C24H29N7O
CAS Number 294646-77-8
Form Solid
Solubility (25°C) DMSO: ≥10 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Xuewen Chen, et al. The Parameters Identification of High-Temperature Constitutive Model Based on Inverse Optimization Method and 3D Processing Map of Cr8 Alloy Steel

[2] Mikołaj Słabicki, et al. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K

[3] Hatem Sallam, et al. Pharmacokinetics and biodistribution of the cyclin-dependent kinase inhibitor -CR8- in mice

[4] Shruti V Kabadi, et al. CR8, a selective and potent CDK inhibitor, provides neuroprotection in experimental traumatic brain injury

[5] K Bettayeb, et al. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases

Related PROTAC Products
GDC-2992

GDC-2992 is an orally active androgen receptor (AR) degrader. GDC-2992 degrads AR with a DC50 value of 2.7 nM and inhibits proliferation with an IC50 valude of 9.7 nM in VCaPcells.

Setidegrasib

Setidegrasib is a PROTAC KRAS degrader (DC50: 37 nM). Setidegrasib induces the degradation of G12D-mutation KRAS protein. Setidegrasib has antitumor effect.

PROTAC HK2 Degrader-1

PROTAC HK2 Degrader-1 is a PROTAC consisting of Lonidamine as a target protein Hexokinase 2 (HK2) inhibitor and Thalidomide as a CRBN ligand-linked PROTAC. PROTAC HK2 Degrader-1 selectively inhibits the proliferation of breast cancer cells by forming a ternary complex through the ubiquitin-proteasome system to degrade Hexokinase 2 (HK2) protein leading to mitochondrial damage and cell death.

ZXH-4-130 TFA

ZXH-4-130 TFA is a highly potent and selective degrader of CRBN. ZXH-4-130 is a CRBN-VHL compound (hetero-PROTAC).

MS4322

MS4322 (YS43-22) is a specific PRMT5 PROTAC degrader. MS4322 reduces the PRMT5 protein level with a DC50 of 1.1 μM in MCF-7 cells. MS4322 inhibits the methyltransferase activity of PRMT5 with an IC50 of 18 nM. MS4322 promotes ubiquitination and degradation of PRMT5.

  Catalog
Abmole Inhibitor Catalog




Keywords: CR8 supplier, PROTAC, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.